Mokari Atabak sold $3.2M of CORT
Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $81.15 ($80.02–$82.45, $3.25M total) across 4 trades on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a fresh, timestamped data point on insider activity (CFO selling ~$3.25M), but it does not include any new operational or financial guidance that would directly reset valuation expectations.
Market read
Useful for monitoring insider behavior and potential sentiment, but likely low incremental trading impact absent other catalysts.
What to watch
Traders may over-weight insider sales; without concurrent guidance, trial, or deal news, the signal is mostly sentiment/positioning rather than valuation.
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reporting an officer sale executed across multiple trades.
Ticker impact
Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares in open-market transactions on 2026-06-15 for ~$3.25M under a 10b5-1 plan.
Likely limited immediate impact; any reaction should be small unless accompanied by other company-specific catalysts.
The filing is primary-source and time-stamped, but it is an officer sale under a pre-arranged plan with no accompanying fundamental change disclosed in the text.
Market effects
No sector read-through; this is a single-company insider transaction with no new regulatory/clinical/product information.
None indicated.
None indicated.
Counterpoint
10b5-1 sales often reflect scheduled liquidity rather than bearish expectations; the sale may not change near-term fundamentals.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction; CFO Mokari Atabak sold shares on 2026-06-15.
- insiderMokari Atabak
Chief Financial Officer who executed the open-market sale under a pre-arranged Rule 10b5-1 plan.
